From pharma to AGI hype, and developing AI in finance: Martin Shkreli’s journey
From Gradient Dissent
Martin Shkreli•Entrepreneur, Investor, former Pharmaceutical CEO
Executive Summary
Martin Shkreli offers a contrarian perspective on AI in drug discovery, arguing the primary bottleneck is identifying biological targets, not generating molecules, and proposes an LLM to synthesize all of PubMed as the most valuable application.
He defends his controversial past, including the drug price hike and his fraud conviction, by framing his actions within capitalist principles and asserting that his hedge fund investors ultimately profited significantly.
Shkreli discusses his experience in federal prison, highlighting the psychological challenge of being disconnected from technology and offering insights into the socio-economic backgrounds of the inmate population.
Despite being banned from the U.S.
pharmaceutical industry, he has successfully launched a new financial software company, securing pre-seed investment from prominent tech founders and achieving millions in revenue.
12 quotes
Concerns Raised
The primary bottleneck in drug discovery is identifying biological targets, a problem current AI approaches are not adequately addressing.
The U.S. justice system is overwhelmingly biased towards conviction and can be weaponized against public figures.
AI for chemistry and molecule generation is an overhyped distraction from the more difficult problems in pharma.
Denying prisoners access to computers and the internet is a form of cruel and unusual punishment in the modern age.
Opportunities Identified
Building a large language model capable of reading and synthesizing all 38 million papers in PubMed to uncover novel biological insights.
Developing drugs for neglected diseases with no current FDA-approved treatments, such as Chagas disease.
AI will significantly enhance quantitative trading, creating an advantage for those who can build and leverage sophisticated models.
The current AI investment cycle is more rational than the dot-com bubble, as today's companies have tangible revenue and products.